Latest News

Notice of Public Comment/Workshops for the Draft Technical Support Document for Exposure Assessment and Stochastic Analysis Nov 2011
OEHHA released for public comment the Air Toxics "Hot Spots" Program Risk Assessment Guidelines: Technical Support Document for Exposure Assessment and Stochastic Analysis.
Nov 7, 2011, Program: Air
Extension of Comment Period - Proposed Amendment To Section 25705 Specific Regulatory Levels Posing No Significant Risk: Imazalil
On September 23, 2011, OEHHA published a notice in the California Regulatory Notice Register (Register 2011, No. 38-Z) proposing to establish a specific regulatory level posing no significant risk for Imazalil by amending Title 27, California Code of Regulations, section 25705.
Nov 7, 2011, Program: Proposition 65
Estrogen–progestogen (combined) used as menopausal therapy, Etoposide, Etoposide in combination with cisplatin and bleomycin, Methyl isobutyl ketone, MOPP (vincristine-prednisone-nitrogen mustard-procarbazine mixture) Listed as Carcinogens
Estrogen–progestogen (combined) used as menopausal therapy, etoposide, etoposide in combination with cisplatin and bleomycin, methyl isobutyl ketone, MOPP (vincristine-prednisone-nitrogen mustard-procarbazine mixture) listed as known to cause cancer under Proposition 65.
Nov 4, 2011, Program: Proposition 65
Meeting Synopsis and Slide Presentations Carcinogen Identification Committee Meeting Held on October 12, 2011
Meeting Synopsis and Slide Presentations Carcinogen Identification Committee Meeting Held on October 12, 2011
Nov 2, 2011, Program: Proposition 65
Extension of Comment Period - Proposed Amendment To Section 25707(B), Route of Exposure: Hexavalent Chromium (VI)
Extension of public comment period regarding the removal of the reference to hexavalent chromium in Section 25707(b)(4) as posing no significant risk when ingested. 
Oct 31, 2011, Program: Proposition 65
tris(1,3-dichloro-2-propyl) phosphate (TDCPP) Listed Effective October 28, 2011 as Known to the State to Cause Cancer
Tris(1,3-dichloro-2-propyl) phosphate (TDCPP) was listed effective 10/28/2011 as known to the State to cause cancer.
Oct 28, 2011, Program: Proposition 65
Hearing - Proposed Amendment To Section 25705 Specific Regulatory Levels Posing No Significant Risk: Imazalil
Extension of comment period regarding the establishment of a specific regulatory level posing no significant risk for Imazalil.
Oct 27, 2011, Program: Proposition 65
Notice of Adoption to Text of Regulations Title 27, California Code of Regulations Amendment to Section 25805 Maximum Allowable Dose Level (MADL) for Avermectin B1
Notice of adoption to text of regulations Title 27, California Code of Regulations amendment to section 25805 Maximum Allowable Dose Level (MADL) for Avermectin B1
Oct 26, 2011, Program: Proposition 65
Extension of Comment Period - Changed Notice of Proposed Rulemaking Specific Regulatory Levels Posing No Significant Risk: 4-Methylimidazole (4-MEI)
Extension of public comment period on the changed notice of proposed rulemaking establishing a  No Significant Risk Level: 4-Methylimidazole (4-MEI).
Oct 24, 2011, Program: Proposition 65
Carcinogen Identification Committee Meeting Scheduled for October 12 and 13, 2011
Announcement of the October 12th and 13th2011 CIC meeting and hazard ID materials for fluoride and its salts, and tris(1,3-Dichloro-2-Propyl) phosphate.  Both will be considered for listing at the October 2011 meeting.
Oct 12, 2011, Program: Proposition 65

Pages